Startups

Christiana Care scientists make colon cancer discovery

The Helen F. Graham Cancer & Research Institute’s findings may lead to new treatment options.

A potential new breakthrough for colon cancer has been discovered in Delaware. (Photo by Flickr user Michael (a.k.a. moik) McCullough, used under a Creative Commons license)

A recent study led by Bruce Boman of Christiana Care Health System, found that colon cancer stem cell activity may be inhibited by retinoic acid signaling. Retinoic acid, a vitamin A–derived molecule often found in topical anti-aging products (Retin-A), is used in cancer treatment due to its affect on cell development.

Colorectal cancer is the second leading cause of cancer-related deaths in the United States. It can be difficult to treat due to drug resistance; this discovery may help oncologists target these cancers with more success.

“Our findings point to a number of possibilities for developing more effective stem cell targeting therapies for advanced colorectal cancer,” Dr. Boman said.

The paper, published in the Oct. 5 issue of Oncotarget, is co-authored by former University of Delaware student researcher Shirin Modarai (who currently works for Christiana Care), among others.

Read the findings
Companies: ChristianaCare

Before you go...

Please consider supporting Technical.ly to keep our independent journalism strong. Unlike most business-focused media outlets, we don’t have a paywall. Instead, we count on your personal and organizational support.

Our services Preferred partners The journalism fund
Engagement

Join our growing Slack community

Join 5,000 tech professionals and entrepreneurs in our community Slack today!

Trending

Delaware’s vision for the year 2276: Quantum, sustainability and, above all, community

This Week in Jobs: 20 smart picks for your next tech career opportunity

10 tech and startup events to jump start your 2025

Technically Media